Comparison of the design differences between the Ginkgo Evaluation of Memory study and the Guidage study

  • J. D. Williamson
  • B. Vellas
  • C. Furberg
  • R. Nahin
  • S. T. Dekosky


The epidemic of late life dementia, prominence of use of alternative medications and supplements, and initiation of efforts to determine how to prevent dementia have led to efforts to conduct studies aimed at prevention of dementia. The GEM (Ginkgo Evaluation of Memory) and GuidAge studies are ongoing randomized double-blind, placebo-controlled trials of Ginkgo biloba, administered in a dose of 120 mg twice per day as EGb761, to test whether Ginkgo biloba is effective in the prevention of dementia (and especially Alzheimer’s disease) in normal elderly or those early cognitive impairment. Both GEM and GuidAge will also add substantial knowledge to the growing need for expertise in designing and implementing clinical trials to test the efficacy of putative disease-modifying agents for the dementias. While there are many similarities between GEM and Guidage, there are also significant differences. We present here the first comparative design and baseline data fromGEM and Guidage, two of the largest dementia primary prevention trials to date.


Dementia Intermittent Claudication Clinical Dementia Rate Ginkgo Extract GuidAge Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Guralnik JM, Leveille SG, Hirsch R, Ferrucci L, Fried LP. The impact of disability on older women. JAMWA 1997;52(3): 113–120.PubMedGoogle Scholar
  2. 2.
    Guero-Torres H, Fratiglioni L, Guo Z, Viitanen M, von SE, Winblad B. Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health 1998 Oct; 88(10): 1452–1456.Google Scholar
  3. 3.
    Magsi H, Malloy T. Undenecognition of cognitive impairment in assisted living facilities. J Am Geriatr Soc 2005 Feb;53(2): 295–298.PubMedCrossRefGoogle Scholar
  4. 4.
    National Institute on Aging. Progress Report on Alzheimer’s Disease. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service; 2000. Report No.: NIH Publication no. 00-4859.Google Scholar
  5. 5.
    Haines DD, Bak I, Ferdinandy P, et al. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts. J Cardiovasc Pharmacol 2000 Jan;35(l): 37–44.PubMedCrossRefGoogle Scholar
  6. 6.
    Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997 Feb;29(2): 733–742.PubMedCrossRefGoogle Scholar
  7. 7.
    Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997 Feb;29(2): 733–742.PubMedCrossRefGoogle Scholar
  8. 8.
    Robak J, Gryglewski RJ. Flavonoids are scavengers of Superoxide anions. Biochem Pharmacol 1988 Mar 1;37(5): 837–841.PubMedCrossRefGoogle Scholar
  9. 9.
    Tosaki A, Engelman DT, Pali T, Engelman RM, Droy-Lefaix MT. Ginkgo biloba extract (EGb 761) improves postischemic function in isolated preconditioned working rat hearts. Coron Artery Dis 1994 May;5(5): 443–450.PubMedCrossRefGoogle Scholar
  10. 10.
    Varga E, Bodi A, Ferdinandy P, Droy-Lefaix MT, Blasig IE, Tosaki A. The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts: a link between cardiac function and nitric oxide production. J Cardiovasc Pharmacol1999 Nov;34(5): 711–717.PubMedCrossRefGoogle Scholar
  11. 11.
    Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000 Feb;71(2): 621S-629S.PubMedGoogle Scholar
  12. 12.
    Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996;36: 83–106.PubMedCrossRefGoogle Scholar
  13. 13.
    Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002 Sep 17;99(19): 12197–12202.PubMedCrossRefGoogle Scholar
  14. 14.
    Rimbach G, Wolffram S, Watanabe C, Packer L, Gohil K. Effect of Ginkgo biloba (EGb 761) on differential gene expression. Pharmacopsychiatry 2003 Jun;36 Suppl 1: S95-S99.PubMedGoogle Scholar
  15. 15.
    Watanabe CM, Wolffram S, Ader P, et al. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba. Proc Natl Acad Sci U S A 2001 Jun 5;98(12): 6577–6580.PubMedCrossRefGoogle Scholar
  16. 16.
    Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 2000 Jun; 12(6): 1882–1890.PubMedCrossRefGoogle Scholar
  17. 17.
    Brunetti L, Orlando G, Menghini L, Ferrante C, Chiavaroli A, Vacca M. Ginkgo biloba leaf extract reverses amyloid beta-peptide-induced isoprostane production in rat brain in vitro. Planta Med 2006 Nov;72(14): 1296–1299.PubMedCrossRefGoogle Scholar
  18. 18.
    Mahady GB. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J Cardiovasc Nurs 2002 Jul;16(4): 21–32.PubMedGoogle Scholar
  19. 19.
    Marcocci L, Maguire JJ, Droy-Lefaix MT, Packer L. The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761. Biochem Biophys Res Commun 1994 Jun 15;201(2): 748–755.PubMedCrossRefGoogle Scholar
  20. 20.
    Rioufol G, Pietri S, Culcasi M, et al. Ginkgo biloba extract EGb 761 attenuates myocardial stunning in the pig heart. Basic Res Cardiol 2003 Feb;98(l): 59–68.PubMedCrossRefGoogle Scholar
  21. 21.
    Huang SY, Jeng C, Kao SC, Yu JJ, Liu DZ. Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin Nutr 2004 Aug;23(4): 615–621.PubMedCrossRefGoogle Scholar
  22. 22.
    Koltringer P, Langsteger W, Klima G, Reisecker F, Eber O. [Hemorheologic effects of ginkgo biloba extract EGb 761. Dose-dependent effect of EGb 761 on microcirculation and viscoelasticity of blood]. Fortschr Med 1993 Apr 10;111(10): 170–172.PubMedGoogle Scholar
  23. 23.
    Auguet M, DeFeudis FV, Clostre F. Effects of Ginkgo biloba on arterial smooth muscle responses to vasoactive stimuli. Gen Pharmacol 1982;13(2): 169–171.PubMedGoogle Scholar
  24. 24.
    Chen X, Salwinski S, Lee TJ. Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. Clin Exp Pharmacol Physiol 1997 Dec;24(12): 958–959.PubMedCrossRefGoogle Scholar
  25. 25.
    Haramaki N, Aggarwal S, Kawabata T, Droy-Lefaix MT, Packer L. Effects of natural antioxidant ginkgo biloba extract (EGB 761) on myocardial ischemia-reperfusion injury. Free Radie Biol Med 1994 Jun;16(6): 789–794.CrossRefGoogle Scholar
  26. 26.
    Sasaki Y, Noguchi T, Yamamoto E, et al. Effects of Ginkgo biloba extract (EGb 761) on cerebral thrombosis and blood pressure in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2002 Nov;29(11): 963–967.PubMedCrossRefGoogle Scholar
  27. 27.
    Fitzl G, Welt K, Schaffranietz L. Myocardium-protective effects of Ginkgo biloba extract (EGb 761) in old rats against acute isobaric hypoxia. An electron microscopic morphometric study. I. Protection of cardiomyocytes. Exp Toxicol Pathol 1996 Jan;48(l): 33–39.PubMedGoogle Scholar
  28. 28.
    Liebgott T, Miollan M, Berchadsky Y, Drieu K, Culcasi M, Pietri S. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res Cardiol 2000 Oct;95(5): 368–377.PubMedCrossRefGoogle Scholar
  29. 29.
    Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000 Mar;108(4): 276–281.PubMedCrossRefGoogle Scholar
  30. 30.
    Birks J, Grimley EV, Van DM. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;(4):CD003120.Google Scholar
  31. 31.
    Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003 May 28;289(20): 2651–2662.PubMedCrossRefGoogle Scholar
  32. 32.
    Williamson JD, Miller ME, Bryan RN, et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol 2007 Jun 18;99(12A): 112i-122i.PubMedCrossRefGoogle Scholar
  33. 33.
    Dekosky ST, Fitzpatrick A, Ives DG, et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 2006 Jun;27(3): 238–253.PubMedCrossRefGoogle Scholar
  34. 34.
    Fitzpatrick AL, Fried LP, Williamson J, et al. Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience. Contemp Clin Trials 2006 Dec;27(6): 541–553.PubMedCrossRefGoogle Scholar
  35. 35.
    Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology 2006 Nov 14;67(9 Suppl 3): S6–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996 Mar;29(2): 47–56.PubMedCrossRefGoogle Scholar
  37. 37.
    Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res 1997 Nov;31(6): 645–655.PubMedCrossRefGoogle Scholar
  38. 38.
    Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993 Nov;43(11): 2412–2414.PubMedGoogle Scholar
  39. 39.
    Rosen WG, Mohs RC., Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984 Nov;141(11): 1356–1364.PubMedGoogle Scholar
  40. 40.
    Lopez OL, Becker JT, Somsak D, Dew MA, Dekosky ST. Awareness of cognitive deficits and anosognosia in probable Alzheimer’s disease. Eur Neurol 1994;34(5): 277–282.PubMedCrossRefGoogle Scholar
  41. 41.
    Kawas C, Segal J, Stewart WF, Corrada M, Thal LJ. A validation study of the Dementia Questionnaire. Arch Neurol 1994 Sep;51(9): 901–906.PubMedGoogle Scholar
  42. 42.
    Jorm AF, Korten AE. Assessment of cognitive decline in the elderly by informant interview. Br J Psychiatry 1988 Feb;152: 209–213.PubMedCrossRefGoogle Scholar
  43. 43.
    Cardebat D, Doyon B, Puel M, Goulet P, Joanette Y. [Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level]. Acta Neurol Belg 1990;90(4): 207–217.PubMedGoogle Scholar
  44. 44.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 Nov;12(3): 189–198.PubMedCrossRefGoogle Scholar
  45. 45.
    Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology 1988 Jun;38(6): 900–903.PubMedGoogle Scholar
  46. 46.
    Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9(3): 179–186.PubMedGoogle Scholar
  47. 47.
    Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol 1955 Oct;19(5): 393–394.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France and Serdi Éditions 2008

Authors and Affiliations

  • J. D. Williamson
    • 1
  • B. Vellas
    • 2
  • C. Furberg
    • 1
  • R. Nahin
    • 3
  • S. T. Dekosky
    • 4
  1. 1.Departments of Medicine and Public Health Sciences and the Kulynych Center for Memory and Cognition ResearchWake Forest University Health SciencesWinston-Salem
  2. 2.CHU Toulouse, Geriatrics DepartmentPurpan University HospitalToulouseFrance
  3. 3.National Center for Complementary and Alternative MedicineNational Institutes of HealthBethesda
  4. 4.Department of NeurologyUniversity of PittsburghPittsburgh

Personalised recommendations